Genome Editing Market: Focus on Technology - Distribution by Type of Gene Editing Technique, Type of Therapy, Gene Editing Approach, Type of Gene Delivery Method, Gene Delivery Modality, Application Area, Type of End User, Key Geographical Regions and Distribution by Type of Payment Method Employed: Industry Trends and Global Forecasts, 2023-2035
The genome editing market is expected to reach USD 3.5 billion by 2023 anticipated to grow at a CAGR of 12.6% during the forecast period 2023-2035.
Genome editing, also known as gene editing, is a genetic engineering technique that allows for the modification of a single gene or a sequence of genes within an organism's genome. In recent years, there has been a growing need for precise genome editing, leading to the development of various tools by gene-editing companies, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR technology. These tools have been widely used to address clinical conditions resulting from genetic abnormalities, including sickle cell disease, Parkinson's disease, hearing loss, peripheral artery disease, spinal muscular atrophy, autoimmune diseases, and other genetic disorders. Gene therapy, with over 300 candidates in clinical trials as of 2023, has emerged as a promising option. In addition, Prophylaxis treatment is another segment that has garnered significant attention in the gene editing market. However, the development of gene-edited drug products requires substantial investment in drug discovery, development, and manufacturing. To ensure the efficient, precise, and safe delivery of these drugs, pharmaceutical companies are relying on novel genome editing technologies developed by genome editing companies. This is expected to improve the clinical outcome of therapeutics by achieving the desired genetic manipulation. With promising results in clinical trials and accelerated drug approvals, the genome editing market is projected to experience significant growth in the coming years.
Report Coverage
Genome editing, also known as gene editing, is a genetic engineering technique that allows for the modification of a single gene or a sequence of genes within an organism's genome. In recent years, there has been a growing need for precise genome editing, leading to the development of various tools by gene-editing companies, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR technology. These tools have been widely used to address clinical conditions resulting from genetic abnormalities, including sickle cell disease, Parkinson's disease, hearing loss, peripheral artery disease, spinal muscular atrophy, autoimmune diseases, and other genetic disorders. Gene therapy, with over 300 candidates in clinical trials as of 2023, has emerged as a promising option. In addition, Prophylaxis treatment is another segment that has garnered significant attention in the gene editing market. However, the development of gene-edited drug products requires substantial investment in drug discovery, development, and manufacturing. To ensure the efficient, precise, and safe delivery of these drugs, pharmaceutical companies are relying on novel genome editing technologies developed by genome editing companies. This is expected to improve the clinical outcome of therapeutics by achieving the desired genetic manipulation. With promising results in clinical trials and accelerated drug approvals, the genome editing market is projected to experience significant growth in the coming years.
Report Coverage
- The report examines genome editing market by categorizing it based on type of gene editing technique, type of therapy, gene editing approach, gene delivery method, gene delivery modality, application area, type of end user, key geographical regions and payment method employed.
- It evaluates the factors impacting market growth, such as drivers, restraints, opportunities, and challenges.
- The report analyzes the potential benefits and barriers within the market and provides insights into the competitive landscape for leading market players.
- It forecasts market segment revenues across three major regions.
- Perform a comprehensive market analysis of genome editing companies, outlining essential parameters like founding year, company size in terms of workforce, headquarters location, operational model, type of gene editing technique (CRISPR-Cas system, meganucleases, TALENs, ZFNs and other techniques), gene editing approach, type of gene delivery method, type of gene delivery modality, highest phase of drug development supported, therapeutic area and application
- Offer comprehensive profiles of genome editing companies, including an overview, establishment year, workforce count, headquarters location, key executives, technology portfolios, recent advancements, and future prospects.
- Conduct a competitive analysis based on service tenure, competitiveness index encompassing type of gene editing technique, gene editing approach, in-silico (CADD) analysis, type of gene delivery method, type of gene delivery modality, highest phase of development supported and application area.
- Analyze recent partnerships within the sustainable packaging market (2018-2023), considering partnership years, models (licensing agreements, research and development agreements, technology integration agreements, etc), partner types, active companies, agreement types, and regional distribution.
- Examination of investments received by genome editing players from 2018 to 2023 details funding instances, amounts, funding types, investors, active players, active investors, and geographical distribution.
- Detailed analysis of patents filed or granted in genome editing domain, considering parameters such as patent types, years, regions, applicant types, leading assignees, benchmarking, and valuation.
- Arcturus Therapeutics
- Avectas
- Beam Therapeutics
- Bio-Sourcing
- Caribou Biosciences
- Century Therapeutics
- CRISPR Therapeutics
- EdiGene
- Editas Medicine
- Flash Therapeutics
- Fortgen
- G+FLAS Life Sciences
- Graphite Bio
- Intellia Therapeutics
- Ntrans Technologies
- OXGENE
- Prime Medicine
- Revvity (formerly known as Horizon Discovery)
- TargetGene Biotechnologies
- Vor Biopharma
- ZeClinics
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past
Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Introduction to Genome Editing
5.2.1. Evolution of Genome Editing
5.2.2. Genome Editing Technologies
5.2.2.1. CRISPR - Cas System
5.2.2.2. Transcription Activator-Like Effector Nucleases (TALENs)
5.2.2.3. Zinc Finger Nucleases (ZFNs)
5.2.2.4. Meganucleases / Homing Endonucleases
5.3. Applications of Genome Editing Technologies
5.4. Other Emerging Technologies
5.5. Concluding Remarks
6. TECHNOLOGY LANDSCAPE
6.1. Chapter Overview
6.2. Genome Editing: Technology Landscape
6.2.1. Analysis by Type of Gene Editing Technique
6.2.2. Analysis by Gene Editing Approach
6.2.3. Analysis by Type of Gene Delivery Method
6.2.4. Analysis by Type of Gene Delivery Modality
6.2.5. Analysis by Highest Phase of Drug Development Supported
6.2.6. Analysis by Therapeutic Area
6.2.7. Analysis by Application Area
6.3. Genome Editing: Technology Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.3.4. Analysis by Operational Model
6.3.5. Most Active Players: Distribution by Number of Technologies
7. TECHNOLOGY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Technology Competitiveness Analysis
7.4.1. Genome Editing Technologies Offered by Players based in North America
7.4.2. Genome Editing Technologies Offered by Players based in Europe
7.4.3. Genome Editing Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Latin America
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Arcturus Therapeutics
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Technology Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. Beam Therapeutics
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Technology Portfolio
8.3.4. Recent Developments and Future Outlook
8.4. Caribou Biosciences
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Technology Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Century Therapeutics
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Technology Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. CRISPR Therapeutics
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Technology Portfolio
8.6.4. Recent Developments and Future Outlook
8.7. Editas Medicine
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Technology Portfolio
8.7.4. Recent Developments and Future Outlook
8.8. Graphite Bio
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Recent Developments and Future Outlook
8.9. Intellia Therapeutics
8.9.1. Company Overview
8.9.2. Financial Information
8.9.3. Technology Portfolio
8.9.4. Recent Developments and Future Outlook
8.10. Prime Medicine
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Recent Developments and Future Outlook
8.11. Vor Biopharma
8.11.1. Company Overview
8.11.2. Technology Portfolio
8.11.3. Recent Developments and Future Outlook
8.12. Other Leading Players
8.12.1. Avectas
8.12.2. Bio-Sourcing
8.12.3. Edigene
8.12.4. Flash Therapeutics
8.12.5. Fortgen
8.12.6. G+FLAS Life Sciences
8.12.7. Ntrans Technologies
8.12.8. OXGENE
8.12.9. Revvity (formerly known as Horizon Discovery)
8.12.10. TargetGene Biotechnologies
8.12.11. ZeClinics
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Genome Editing Technologies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Location of Headquarters of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Analysis by Geography
9.3.7.1. Local and International Agreements
9.3.7.2. Intercontinental and Intracontinental Agreements
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Genome Editing Domain: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Type of Patent and Publication Year
10.3.3. Analysis by Geography
10.3.4. Analysis by CPC Symbols
10.3.5. Leading Industry Players: Analysis by Number of Patents
10.4. Genome Editing Domain: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.2. Analysis by Leading Industry Players
10.5. Patent Valuation Analysis
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Genome Editing Domain: Funding and Investment Analysis
11.3.1. Analysis by Year of Investment
11.3.1.1. Cumulative Year-wise Trend of Funding Instances
11.3.1.2. Cumulative Year-wise Trend of Amount Invested
11.3.2. Analysis by Type of Funding
11.3.2.1. Analysis of Funding Instances
11.3.2.2. Analysis of Amount Invested
11.3.3. Analysis by Year and Type of Funding
11.3.4. Analysis by Geography
11.3.5. Most Active Players: Analysis by Amount Invested and Number of Funding Instances
11.3.6. Leading Investors: Analysis by Number of Funding Instances
12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
12.1. Chapter Overview
12.2. Market Drivers
12.3. Market Restraints
12.4. Market Opportunities
12.5. Market Challenges
12.6. Conclusion
13. GENOME EDITING TECHNOLOGIES MARKET
13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Genome Editing Technologies Market, Forecasted Estimates (2023-2035)
13.3.1. Scenario Analysis
13.4. Key Market Segmentations
13.5. Dynamic Dashboard
14. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. CRISPR-Cas System: Forecasted Estimates (2023-2035)
14.4. TALENs: Forecasted Estimates (2023-2035)
14.5. Meganucleases: Forecasted Estimates (2023-2035)
14.6. ZFNs: Forecasted Estimates (2023-2035)
14.7. Other Techniques: Forecasted Estimates (2023-2035)
14.8. Data Triangulation
14.8.1. Insights from Primary Research
14.8.2. Insights from Secondary Research
14.8.3. Insights from In-house Repository
15. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Cell Therapies: Forecasted Estimates (2023-2035)
15.4. Gene Therapies: Forecasted Estimates (2023-2035)
15.5. Other Therapies: Forecasted Estimates (2023-2035)
15.6. Data Triangulation
15.6.1. Insights from Primary Research
15.6.2. Insights from Secondary Research
15.6.3. Insights from In-house Repository
16. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Gene Knock-Out Approaches: Forecasted Estimates (2023-2035)
16.4. Gene Knock-In Approaches: Forecasted Estimates (2023-2035)
16.5. Data Triangulation
16.5.1. Insights from Primary Research
16.5.2. Insights from Secondary Research
16.5.3. Insights from In-house Repository
17. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Ex-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
17.4. In-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
17.5. Data Triangulation
17.5.1. Insights from Primary Research
17.5.2. Insights from Secondary Research
17.5.3. Insights from In-house Repository
18. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Viral Vectors: Forecasted Estimates (2023-2035)
18.4. Non-Viral Vectors: Forecasted Estimates (2023-2035)
18.5. Data Triangulation
18.5.1. Insights from Primary Research
18.5.2. Insights from Secondary Research
18.5.3. Insights from In-house Repository
19. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Drug Discovery and Development: Forecasted Estimates (2023-2035)
19.4. Diagnostics: Forecasted Estimates (2023-2035)
19.5. Data Triangulation
19.5.1. Insights from Primary Research
19.5.2. Insights from Secondary Research
19.5.3. Insights from In-house Repository
20. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Pharmaceutical and Biotechnology Companies: Forecasted Estimates (2023-2035)
20.4. Academic and Research Institutes: Forecasted Estimates (2023-2035)
20.5. Data Triangulation
20.5.1. Insights from Primary Research
20.5.2. Insights from Secondary Research
20.5.3. Insights from In-house Repository
21. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. North America: Forecasted Estimates (2023-2035)
21.4. Europe: Forecasted Estimates (2023-2035)
21.5. Asia-Pacific: Forecasted Estimates (2023-2035)
21.6. Data Triangulation
21.6.1. Insights from Primary Research
21.6.2. Insights from Secondary Research
21.6.3. Insights from In-house Repository
22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Milestone Payments: Forecasted Estimates (2023-2035)
22.4. Upfront Payments: Forecasted Estimates (2023-2035)
22.5. Data Triangulation
22.5.1. Insights from Primary Research
22.5.2. Insights from Secondary Research
22.5.3. Insights from In-house Repository
23. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS
23.1. Chapter Overview
23.2. Leading Industry Players
24. CONCLUSION
25. EXECUTIVE INSIGHTS
26. APPENDIX 1: TABULATED DATA
27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past
Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Introduction to Genome Editing
5.2.1. Evolution of Genome Editing
5.2.2. Genome Editing Technologies
5.2.2.1. CRISPR - Cas System
5.2.2.2. Transcription Activator-Like Effector Nucleases (TALENs)
5.2.2.3. Zinc Finger Nucleases (ZFNs)
5.2.2.4. Meganucleases / Homing Endonucleases
5.3. Applications of Genome Editing Technologies
5.4. Other Emerging Technologies
5.5. Concluding Remarks
6. TECHNOLOGY LANDSCAPE
6.1. Chapter Overview
6.2. Genome Editing: Technology Landscape
6.2.1. Analysis by Type of Gene Editing Technique
6.2.2. Analysis by Gene Editing Approach
6.2.3. Analysis by Type of Gene Delivery Method
6.2.4. Analysis by Type of Gene Delivery Modality
6.2.5. Analysis by Highest Phase of Drug Development Supported
6.2.6. Analysis by Therapeutic Area
6.2.7. Analysis by Application Area
6.3. Genome Editing: Technology Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.3.4. Analysis by Operational Model
6.3.5. Most Active Players: Distribution by Number of Technologies
7. TECHNOLOGY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Technology Competitiveness Analysis
7.4.1. Genome Editing Technologies Offered by Players based in North America
7.4.2. Genome Editing Technologies Offered by Players based in Europe
7.4.3. Genome Editing Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Latin America
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Arcturus Therapeutics
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Technology Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. Beam Therapeutics
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Technology Portfolio
8.3.4. Recent Developments and Future Outlook
8.4. Caribou Biosciences
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Technology Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Century Therapeutics
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Technology Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. CRISPR Therapeutics
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Technology Portfolio
8.6.4. Recent Developments and Future Outlook
8.7. Editas Medicine
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Technology Portfolio
8.7.4. Recent Developments and Future Outlook
8.8. Graphite Bio
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Recent Developments and Future Outlook
8.9. Intellia Therapeutics
8.9.1. Company Overview
8.9.2. Financial Information
8.9.3. Technology Portfolio
8.9.4. Recent Developments and Future Outlook
8.10. Prime Medicine
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Recent Developments and Future Outlook
8.11. Vor Biopharma
8.11.1. Company Overview
8.11.2. Technology Portfolio
8.11.3. Recent Developments and Future Outlook
8.12. Other Leading Players
8.12.1. Avectas
8.12.2. Bio-Sourcing
8.12.3. Edigene
8.12.4. Flash Therapeutics
8.12.5. Fortgen
8.12.6. G+FLAS Life Sciences
8.12.7. Ntrans Technologies
8.12.8. OXGENE
8.12.9. Revvity (formerly known as Horizon Discovery)
8.12.10. TargetGene Biotechnologies
8.12.11. ZeClinics
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Genome Editing Technologies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Location of Headquarters of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Analysis by Geography
9.3.7.1. Local and International Agreements
9.3.7.2. Intercontinental and Intracontinental Agreements
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Genome Editing Domain: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Type of Patent and Publication Year
10.3.3. Analysis by Geography
10.3.4. Analysis by CPC Symbols
10.3.5. Leading Industry Players: Analysis by Number of Patents
10.4. Genome Editing Domain: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.2. Analysis by Leading Industry Players
10.5. Patent Valuation Analysis
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Genome Editing Domain: Funding and Investment Analysis
11.3.1. Analysis by Year of Investment
11.3.1.1. Cumulative Year-wise Trend of Funding Instances
11.3.1.2. Cumulative Year-wise Trend of Amount Invested
11.3.2. Analysis by Type of Funding
11.3.2.1. Analysis of Funding Instances
11.3.2.2. Analysis of Amount Invested
11.3.3. Analysis by Year and Type of Funding
11.3.4. Analysis by Geography
11.3.5. Most Active Players: Analysis by Amount Invested and Number of Funding Instances
11.3.6. Leading Investors: Analysis by Number of Funding Instances
12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
12.1. Chapter Overview
12.2. Market Drivers
12.3. Market Restraints
12.4. Market Opportunities
12.5. Market Challenges
12.6. Conclusion
13. GENOME EDITING TECHNOLOGIES MARKET
13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Genome Editing Technologies Market, Forecasted Estimates (2023-2035)
13.3.1. Scenario Analysis
13.4. Key Market Segmentations
13.5. Dynamic Dashboard
14. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. CRISPR-Cas System: Forecasted Estimates (2023-2035)
14.4. TALENs: Forecasted Estimates (2023-2035)
14.5. Meganucleases: Forecasted Estimates (2023-2035)
14.6. ZFNs: Forecasted Estimates (2023-2035)
14.7. Other Techniques: Forecasted Estimates (2023-2035)
14.8. Data Triangulation
14.8.1. Insights from Primary Research
14.8.2. Insights from Secondary Research
14.8.3. Insights from In-house Repository
15. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Cell Therapies: Forecasted Estimates (2023-2035)
15.4. Gene Therapies: Forecasted Estimates (2023-2035)
15.5. Other Therapies: Forecasted Estimates (2023-2035)
15.6. Data Triangulation
15.6.1. Insights from Primary Research
15.6.2. Insights from Secondary Research
15.6.3. Insights from In-house Repository
16. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Gene Knock-Out Approaches: Forecasted Estimates (2023-2035)
16.4. Gene Knock-In Approaches: Forecasted Estimates (2023-2035)
16.5. Data Triangulation
16.5.1. Insights from Primary Research
16.5.2. Insights from Secondary Research
16.5.3. Insights from In-house Repository
17. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Ex-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
17.4. In-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
17.5. Data Triangulation
17.5.1. Insights from Primary Research
17.5.2. Insights from Secondary Research
17.5.3. Insights from In-house Repository
18. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Viral Vectors: Forecasted Estimates (2023-2035)
18.4. Non-Viral Vectors: Forecasted Estimates (2023-2035)
18.5. Data Triangulation
18.5.1. Insights from Primary Research
18.5.2. Insights from Secondary Research
18.5.3. Insights from In-house Repository
19. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Drug Discovery and Development: Forecasted Estimates (2023-2035)
19.4. Diagnostics: Forecasted Estimates (2023-2035)
19.5. Data Triangulation
19.5.1. Insights from Primary Research
19.5.2. Insights from Secondary Research
19.5.3. Insights from In-house Repository
20. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Pharmaceutical and Biotechnology Companies: Forecasted Estimates (2023-2035)
20.4. Academic and Research Institutes: Forecasted Estimates (2023-2035)
20.5. Data Triangulation
20.5.1. Insights from Primary Research
20.5.2. Insights from Secondary Research
20.5.3. Insights from In-house Repository
21. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. North America: Forecasted Estimates (2023-2035)
21.4. Europe: Forecasted Estimates (2023-2035)
21.5. Asia-Pacific: Forecasted Estimates (2023-2035)
21.6. Data Triangulation
21.6.1. Insights from Primary Research
21.6.2. Insights from Secondary Research
21.6.3. Insights from In-house Repository
22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Milestone Payments: Forecasted Estimates (2023-2035)
22.4. Upfront Payments: Forecasted Estimates (2023-2035)
22.5. Data Triangulation
22.5.1. Insights from Primary Research
22.5.2. Insights from Secondary Research
22.5.3. Insights from In-house Repository
23. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS
23.1. Chapter Overview
23.2. Leading Industry Players
24. CONCLUSION
25. EXECUTIVE INSIGHTS
26. APPENDIX 1: TABULATED DATA
27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
